Medexus Pharmaceuticals (MDP) Competitors

Canopy Growth (TSE:WEED) and Medexus Pharmaceuticals (TSE:MDP) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Which has more risk and volatility, WEED or MDP?

Canopy Growth has a beta of 1.79, indicating that its share price is 79% more volatile than the S&P 500. Comparatively, Medexus Pharmaceuticals has a beta of 1.96, indicating that its share price is 96% more volatile than the S&P 500.

Which has better valuation & earnings, WEED or MDP?

Medexus Pharmaceuticals has lower revenue, but higher earnings than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than Medexus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Canopy Growth	C$519.68M	0.64	-C$1.05B	-C$6.85	-0.30
Medexus Pharmaceuticals	C$100.25M	0.61	C$3.26M	C$0.21	13.15

Does the media prefer WEED or MDP?

In the previous week, Canopy Growth had 1 more articles in the media than Medexus Pharmaceuticals. MarketBeat recorded 7 mentions for Canopy Growth and 6 mentions for Medexus Pharmaceuticals. Medexus Pharmaceuticals' average media sentiment score of 0.64 beat Canopy Growth's score of 0.32 indicating that Medexus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Canopy Growth	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Medexus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer WEED or MDP?

Canopy Growth currently has a consensus target price of C$1.55, suggesting a potential downside of 25.12%. Medexus Pharmaceuticals has a consensus target price of C$5.49, suggesting a potential upside of 99.55%. Given Medexus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Medexus Pharmaceuticals is more favorable than Canopy Growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Canopy Growth	2 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Medexus Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	4 Strong Buy rating(s)	3.29

Is WEED or MDP more profitable?

Medexus Pharmaceuticals has a net margin of 3.25% compared to Canopy Growth's net margin of -201.27%. Medexus Pharmaceuticals' return on equity of 11.07% beat Canopy Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Canopy Growth	-201.27%	-108.18%	-3.83%
Medexus Pharmaceuticals	3.25%	11.07%	4.89%

Do institutionals and insiders hold more shares of WEED or MDP?

9.4% of Canopy Growth shares are held by institutional investors. Comparatively, 8.3% of Medexus Pharmaceuticals shares are held by institutional investors. 0.2% of Canopy Growth shares are held by company insiders. Comparatively, 9.1% of Medexus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Medexus Pharmaceuticals beats Canopy Growth on 13 of the 17 factors compared between the two stocks.